BioCatalyst

AMP945 ascending doses, AMP945 RP2D — catalyst calendar

1 verified catalyst event(s) referencing AMP945 ascending doses, AMP945 RP2D, each linked to its official source. Verified as of 2026-10-02.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02-01
in 4mo
ESTIMATED
 READOUT
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment
Phase 1/2 · Pancreatic Cancer, PDAC
 Amplia Therapeutics Limited AMP945 ascending doses, AMP945 RP2D ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.